Skip to main content

Table 3 Model Results (Projected Lifetime Outcomes) in Gaucher Disease Type 1

From: A new framework for evaluating the health impacts of treatment for Gaucher disease type 1

 

Starting Health State

   

Intact Spleen

No Spleen

Mild

Moderate

Marked with SSC

Mild

Moderate

Marked with SSC

Discounted QALYs

15.73

15.69

14.92

15.70

15.65

14.89

Undiscounted QALYs

31.16

31.20

29.73

31.13

31.16

29.71

% of Remaining Lifetime Spent in:

 Mild

69.72

70.61

33.86

68.94

69.57

19.55

 Mild with BP

12.86

12.26

16.13

13.15

12.23

13.37

 Mild with SSC

0.73

0.69

1.17

0.75

0.70

1.07

 Moderate

15.69

15.58

42.20

16.14

16.50

52.97

 Moderate with SSC

0.53

0.46

2.76

0.55

0.54

5.40

 Marked

0.24

0.21

1.36

0.25

0.24

3.01

 Marked with SSC

0.20

0.17

2.38

0.21

0.20

3.02

 Severe

0.01

0.00

0.03

0.01

0.01

1.28

 Severe with SSC

0.02

0.02

0.12

0.02

0.02

0.33

  1. Results for cohorts starting treatment at age 32 (patients in all cohorts have 42.29 remaining life years). QALYs discounted 3.5% per annum